Tibotec Pharmaceuticals Ltd., based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Yardley, PA. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need.
Tibotec Pharmaceuticals is developing a Global Access Program to facilitate access to its antiretrovirals for patients living with HIV/AIDS in developing countries. The Global Access Program for PREZISTA includes access pricing, registration, medical education for appropriate use and voluntary licensing.
About Tibotec
Tibotec, a division of Janssen-Cilag, will bring innovative products for HIV/AIDS to patients in Europe, the Middle East and Africa. This new division was created within the Janssen-Cilag companies in October 2005 to focus on patients' and health care providers' specific needs in this disease domain. The company will also commercialise medicine against other viral diseases in the future.
Janssen-Cilag
Janssen-Cilag is a leader in traditional and biological medicines for disorders such as in gastroenterology, women's health, mental health and neurology as well as for pain, oncology, haematology and nephrology.
(i) "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected
Adults and Adolescents," DHHS Panel on Antiretroviral Guidelines for
Adults and Adolescents - A Working Group of the Office of AIDS
Research Advisory Council (OARAC); Accessed at:
http://aidsinfo.nih.gov/ContentFiles/Adu...; last
updated October 10, 2006.
Web site: http://www.tibotec.com
Kellie McLaughlin, mobile: +1-609-466-3808; or Hans Vanavermaete, mobile: +32-478-447-278
